Cidara Therapeutics Inc (NASDAQ: CDTX) flaunted slowness of -3.13% at $62.82, as the Stock market unbolted on Thursday, before settling in for the price of $64.85 at the close. Taking a more long-term approach, CDTX posted a 52-week range of $10.14-$66.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 1.30%. Meanwhile, its Annual Earning per share during the time was 1.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 71.53%. This publicly-traded company’s shares outstanding now amounts to $22.12 million, simultaneously with a float of $17.49 million. The organization now has a market capitalization sitting at $1.39 billion. At the time of writing, stock’s 50-day Moving Average stood at $36.83, while the 200-day Moving Average is $23.74.
Cidara Therapeutics Inc (CDTX) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Cidara Therapeutics Inc industry. Cidara Therapeutics Inc’s current insider ownership accounts for 20.93%, in contrast to 47.25% institutional ownership. According to the most recent insider trade that took place on Jun 26 ’25, this organization’s Director bought 2,272,727 shares at the rate of 44.00, making the entire transaction reach 99,999,988 in total value, affecting insider ownership by 3,365,523. Preceding that transaction, on Jun 02 ’25, Company’s Director bought 2,270 for 21.71, making the whole transaction’s value amount to 49,281. This particular insider is now the holder of 2,270 in total.
Cidara Therapeutics Inc (CDTX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.73 per share during the current fiscal year.
Cidara Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 71.53% and is forecasted to reach -7.58 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 36.71% through the next 5 years, which can be compared against the 1.30% growth it accomplished over the previous five years trading on the market.
Cidara Therapeutics Inc (NASDAQ: CDTX) Trading Performance Indicators
Let’s observe the current performance indicators for Cidara Therapeutics Inc (CDTX). It’s Quick Ratio in the last reported quarter now stands at 3.87. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4631.40.
In the same vein, CDTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -29.07, a figure that is expected to reach -1.95 in the next quarter, and analysts are predicting that it will be -7.58 at the market close of one year from today.
Technical Analysis of Cidara Therapeutics Inc (CDTX)
Now, what If we examine the latest scores posted by [Cidara Therapeutics Inc, CDTX]. During the last 5-days, its volume was better the volume of 0.37 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 86.87% While, its Average True Range was 71.23%.
Raw Stochastic average of Cidara Therapeutics Inc (CDTX) in the period of the previous 100 days is set at 92.03%, which indicates a major rise in contrast to 80.68% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 4.64 that was higher than 2.42 volatility it exhibited in the past 100-days period.
